Touchstone
Last syncOct 31, 2026, 6:54 PM ET

IDYA

Ideaya Biosciences, Inc. Health Care Pharmaceutical Preparations Russell 3000
$31.96Close $2.8BMarket cap $27.60 – $42.4852-week range Nov 3, 2026Next report

Highlights

Cautions

  • Not in an uptrend 3 of 8 trend conditions
  • Lagging the market RS 40 · weaker than 60% of stocks over 12 months
  • Distribution down-day volume 1.6× up-day volume over 50 sessions
  • Results soon Nov 3, 2026, in 2 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 4, 2026
Off 12-month high 25%
1wk down 7.9% price change
1mo down 16.8% price change
12-month return up 1% market up 11% · its own down 12%
F-score — — Not assessed
Altman Z 18.94 Low risk
P/E — price / earnings
PEG — P/E / EPS growth
P/B 2.7× price / book
Earnings yield down 5.9% EBIT / enterprise value
Cheaper than 29% of the market · expensive
Revenue growth up 3024% year on year
EPS growth — latest quarter
Sales growth — latest quarter
ROE down 11% return on equity
Free cash margin down 34% -$73.5M FCF
D/E — long-term debt / equity
Net debt / EBITDA —
Interest cover —EBIT / interest
Piotroski tests

Repair signals

  • Revenue reaccelerating (-70% then +3024%)

Trade setup

ATR% 4.7% $1.52 a day · 2×ATR $28.92
RS 40 / 99 vs the universe
Trend 3 / 8 trend template
Relative volume 1.0× vs 50-day average
Up/down volume 0.61 50 sessions
Implied move — no option chain · report Nov 3, 2026
Trend template · 3 of 8
  • Price above the 150 and 200-day averages: fails
  • 150-day average above the 200-day: passes
  • 200-day average rising for a month: fails
  • 50-day average above the 150 and 200-day: passes
  • Price above the 50-day average: fails
  • At least 30% above the 52-week low: fails
  • Within 25% of the 52-week high: passes
  • RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking
Last reported Aug 4, 2026
Results reaction Aug 4, 20260% vs market2 sessions after results

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $218.7M +3024% on FY2024
$0 $250M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $19.5M FY2021 · $27.9M FY2022 · $50.9M FY2023 · $23.4M FY2024 · $7.0M FY2025 · $218.7M
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$113.7M
-$500M $0 FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · -$34.5M FY2021 · -$49.8M FY2022 · -$58.7M FY2023 · -$113.0M FY2024 · -$274.5M FY2025 · -$113.7M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$73.5M
-$500M $0 $100M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $55.0M FY2021 · -$58.4M FY2022 · -$90.6M FY2023 · -$117.6M FY2024 · -$251.4M FY2025 · -$73.5M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Net -52%
  • Free cash -34%
-5000% 0% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Net -177% · Free cash 281% FY2021 · Net -178% · Free cash -209% FY2022 · Net -115% · Free cash -178% FY2023 · Net -483% · Free cash -503% FY2024 · Net -3921% · Free cash -3592% FY2025 · Net -52% · Free cash -34%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology
  • Cash
  • Long-term debt
$0 $200M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $72.0M FY2021 · Cash $92.0M FY2022 · Cash $68.6M FY2023 · Cash $157.0M FY2024 · Cash $84.4M FY2025 · Cash $112.8M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 87.80m +197.2% since FY2020
87.80m 29.54m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 29.54m FY2021 · 38.53m FY2022 · 48.19m FY2023 · 65.04m FY2024 · 86.50m FY2025 · 87.80m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $19.5M $27.9M $50.9M $23.4M $7.0M $218.7M
Operating income -$35.3M -$50.3M -$62.5M -$134.4M -$327.0M -$159.3M
Net income -$34.5M -$49.8M -$58.7M -$113.0M -$274.5M -$113.7M
Net margin -177% -178% -115% -483% -3921% -52%
Earnings per share -$1.40 -$1.41 -$1.42 -$1.96 -$3.36 -$1.28
Free cash flow $55.0M -$58.4M -$90.6M -$117.6M -$251.4M -$73.5M
Free cash margin 281% -209% -178% -503% -3592% -34%
Cash $72.0M $92.0M $68.6M $157.0M $84.4M $112.8M
Shareholders' equity $198.3M $301.5M $349.5M $621.1M $1.1B $1.0B
Shares outstanding 29.54m 38.53m 48.19m 65.04m 86.50m 87.80m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 4, 2026 Quarterly ↗ Jun 30, 2026 35d
May 5, 2026 Quarterly ↗ Mar 31, 2026 35d
Feb 17, 2026 Annual ↗ Dec 31, 2025 48d
Nov 4, 2025 Quarterly ↗ Sep 30, 2025 35d
Aug 5, 2025 Quarterly ↗ Jun 30, 2025 36d
May 6, 2025 Quarterly ↗ Mar 31, 2025 36d
Feb 18, 2025 Annual ↗ Dec 31, 2024 49d
Nov 4, 2024 Quarterly ↗ Sep 30, 2024 35d
Aug 6, 2024 Quarterly ↗ Jun 30, 2024 37d
May 7, 2024 Quarterly ↗ Mar 31, 2024 37d
Feb 20, 2024 Annual ↗ Dec 31, 2023 51d
Nov 7, 2023 Quarterly ↗ Sep 30, 2023 38d

Current reports

FiledDisclosed
Aug 4, 2026 Results ↗
Jun 23, 2026 Shareholder vote · Other events ↗
Jun 10, 2026 Other events ↗
Jun 3, 2026 Other events ↗
Jun 1, 2026 Regulation FD · Other events ↗
May 5, 2026 Other events ↗
May 5, 2026 Results ↗
Apr 13, 2026 Other events ↗
Apr 9, 2026 Other events ↗
Feb 17, 2026 Results ↗
Jan 12, 2026 Other events ↗
Jan 12, 2026 Regulation FD ↗